๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Early Hormone Receptor-positive Breast Cancer

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites๐Ÿ“ Birmingham๐Ÿ“ Scottsdale๐Ÿ“ Tucson QuantumLeap Healthcare Collaborative ยท Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trasโ€ฆ A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer NCT06781996Phase 31 site๐Ÿ“ Villejuif Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: multimodal Resilienceยฉ digital companion, Standard supportive care Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer NCT07214532NA49 sites๐Ÿ“ Phoenix๐Ÿ“ Scottsdale๐Ÿ“ Tucson Natera, Inc. ยท Tests: ctDNA-Guided Treatment Strategy Effects of Physical Activity in Early Stage Hormone Receptor Positive Breast Cancer Patients NCT07539038n/a1 site๐Ÿ“ Aviano Centro di Riferimento Oncologico - Aviano Tirzepatide Weight Loss for MRD+ Early Breast Cancer NCT06517212Phase 21 site๐Ÿ“ Dallas Baylor Research Institute ยท Tests: Tirzepatide Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab NCT05760612Phase 31 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Trastuzumab and neratinib, Trastuzumab and Pertuzumab Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer NCT06341894Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: Dalpiciclib, Endocrine therapy Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer NCT06106477NA1 site๐Ÿ“ Milwaukee Medical College of Wisconsin ยท Tests: Intermittent Fasting ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer NCT06970912Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy, Taxane-Based Neoadjuvant Chemotherapy Ablation Compare With Surgery for Early Breast Cancer NCT07484087NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: breast conserving surgery, cryo-thermal ablation Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer NCT05020860Phase 22 sites๐Ÿ“ Houston๐Ÿ“ Houston Baylor Breast Care Center ยท Tests: Paclitaxel, Carboplatin, Trastuzumab, Pertuzumab, Doxorubicin Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer NCT06518837Phase 27 sites๐Ÿ“ Elizabeth๐Ÿ“ Hamilton๐Ÿ“ Livingston Rutgers, The State University of New Jersey ยท Tests: Tirzepatide Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer NCT06534125NA4 sites๐Ÿ“ Atlanta๐Ÿ“ Atlanta๐Ÿ“ Atlanta Emory University ยท Tests: Acupressure Therapy, Acupuncture Therapy, Aromatase Inhibition Therapy, Discussion, Survey Administration CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment NCT07366112Phase 21 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: CDK4/6 inhibitor with endocrine therapy Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy NCT04278469NA1 site๐Ÿ“ Seoul Gencurix, Inc. ยท Tests: Chemotherapy Drugs, Cancer Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635Phase 217 sites๐Ÿ“ Santa Monica๐Ÿ“ Skokie๐Ÿ“ Billings Merck Sharp & Dohme LLC ยท Tests: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer NCT07401381Phase 121 sites๐Ÿ“ Beverly Hills๐Ÿ“ Margate๐Ÿ“ Port Orange Rovi Pharmaceuticals Laboratories ยท Tests: US-sourced oral Femaraยฎ + Letrozole SIE, EU sourced oral Femaraยฎ + Letrozole SIE RADIANT: Pre-op Radiation With Abemaciclib and Letrozole NCT06139107Phase 14 sites๐Ÿ“ Belleville๐Ÿ“ Livingston๐Ÿ“ New Brunswick Mridula George, MD ยท Tests: Abemaciclib, Letrozole the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer NCT07380646Phase 21 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Treat Regimen Adherence to Aromatase Inhibitors ยฑ Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer NCT06650423n/a1 site๐Ÿ“ Ljubljana Institute of Oncology Ljubljana The Benefits of Continued Use of Ovarian Function Suppression After 5 Years NCT06050109n/a1 site๐Ÿ“ Wuhan Hongmei Zheng, PhD ยท Tests: OFS continues to use group after 5 years use, Immunohistochemical detection of HR status Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy NCT07400523Phase 34 sites๐Ÿ“ Zhanjiang๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Ribociclib plus aromatase inhibitor, Aromatase inhibitor Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive๏ผŒ Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer NCT07796880Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Culmerciclib, Aromatase Inhibitor (AI) NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. NCT06781281n/a1 site๐Ÿ“ Zhengzhou Henan Cancer Hospital ยท Tests: Serplulimab, NabPE Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer NCT05878314n/a1 site๐Ÿ“ Tรผbingen University Hospital Tuebingen Real-life Evaluation of Endopredictยฎ in Early HR+/HER2- Breast Cancer NCT07379918n/a1 site๐Ÿ“ Paris Assistance Publique - Hรดpitaux de Paris ยท Tests: Endopredict test A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer NCT07310420Phase 126 sites๐Ÿ“ Hot Springs๐Ÿ“ Washington D.C.๐Ÿ“ Ocoee TerSera Therapeutics LLC ยท Tests: ZOLADEX A Study of the TheraBionic P1 Device in Breast Cancer NCT07218432NA8 sites๐Ÿ“ Clarkston๐Ÿ“ Detroit๐Ÿ“ Farmington Hills Barbara Ann Karmanos Cancer Institute ยท Tests: TheraBionic P1 Device Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: Dalpiciclib, Pyrotinib, SHR-A1811, SHR-1316, Camrelizumab A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700Phase 3331 sites๐Ÿ“ Gilbert๐Ÿ“ Phoenix๐Ÿ“ Tucson Merck Sharp & Dohme LLC ยท Tests: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy